News und Analysen
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
The Humana Foundation Awards Nearly $1 Million in a Second Year Investment to Kingsley House and Growing Local Food Collaborative
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, announces its second year of investments, totaling nearly $1 million in two local projects in the greater
Epic and Humana Deliver on Commitment to Enhance Connectivity and Collaboration Among Patients, Providers, and Health Plans
Humana Inc. (NYSE: HUM), a leading health and well-being company, and Epic, developer of the nation’s most widely used comprehensive health record, have completed the first stage of a joint effort
Boehringer Ingelheim Makes Rapid Shift to Digital Engagement with Veeva CRM Engage Meeting
Boehringer Ingelheim, a top 20 global pharmaceutical company, is standardizing on Veeva CRM Engage Meeting to drive more valued interactions between its global field organization and healthcare
Boehringer Ingelheim Makes Rapid Shift to Digital Engagement with Veeva CRM Engage Meeting
Boehringer Ingelheim, a top 20 global pharmaceutical company, is standardizing on Veeva CRM Engage Meeting to drive more valued interactions between its global field organization and healthcare
Charles River Laboratories Announces Closing of Senior Notes Offering
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 3.750% senior
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) announced today that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the
Humana Adds H Mart to List of National Retailers for Healthy Foods Card Benefit
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies and H Mart, the largest Asian supermarket chain in the U.S., announced today a collaboration to combat food
Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2021. The purpose of
Dexcom Promotes Jereme Sylvain to Chief Financial Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Jereme Sylvain to the role of Executive Vice President and Chief
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology, and EVER
Recordati Rare Diseases: Positive Ergebnisse aus der Phase-III-Studie LINC 4, die heute auf der Jahrestagung der Endocrine Society vorgelegt wurden, bestärken die Wirksamkeit und Sicherheit von Isturisa® (Osilodrostat) bei Morbus Cushing
Recordati Rare Diseases gibt bekannt, dass positive Ergebnisse aus der Phase-III-Studie LINC 4 zu Isturisa® am 22. März auf der Jahrestagung der Endocrine Society präsentiert wurden.1
Ergebnisse
Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual Meeting Reinforce the Efficacy and Safety of Isturisa® (osilodrostat) in Cushing’s Disease
Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa® were presented on March 22 at The Endocrine Society’s Annual Meeting.1
Results from LINC 4
VALBIOTIS erhält die ISO 9001-Zertifizierung für seine Aktivitäten im Bereich „Design, Entwicklung und Produktionskontrolle von Lösungen zur Vorbeugung und Bekämpfung von Stoffwechsel- und Herz-Kreislauf-Erkrankungen“
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL/PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
VALBIOTIS Obtains ISO 9001 Certification for Its Activities in "Design, Development and Production Control of Solutions for Preventing and Combating Metabolic and Cardiovascular Diseases"
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a French Research & Development company committed to scientific innovation for preventing and combating
Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place today in an oral presentation at
VALBIOTIS veröffentlicht seine Jahresbilanz 2020
Pflichtmitteilung:
Highlights und Ergebnisse 2020
-
Globale strategische Partnerschaft mit Nestlé Health Science zur Entwicklung und Vermarktung von TOTUM-63, einem pflanzlichen Wirkstoff mit
Quidel Corporation Applauds Biden Administration Plan to Expand COVID-19 Testing
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its support for the
Illumina Announces Board Changes
Illumina, Inc. (NASDAQ: ILMN) (the “Company”) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company’s new Chair
Waters Peptide Multi-Attribute Method for BioAccord System Boosts Innovator and Biosimilar Drug Development and Commercialization
Waters Corporation (NYSE:WAT) today introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ BioAccord™ LC-MS System, enabling drug development, manufacturing, and QC
Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’), a late-stage clinical biotechnology company pioneering physics-based approaches to
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) released details
Agilent Announces Cash Dividend of 19.4 Cents per Share
Agilent Technologies, Inc. (NYSE: A) today announced that a quarterly dividend of 19.4 cents per share of common stock will be paid on April 28, 2021, to all shareholders of record as of the close